Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) CAO Andrea Sabens sold 386 shares of the stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $62.87, for a total value of $24,267.82. Following the sale, the chief accounting officer now directly owns 64,441 shares of the company’s stock, valued at $4,051,405.67. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of NASDAQ LNTH traded up $1.18 during trading hours on Friday, hitting $60.72. The company had a trading volume of 1,838,969 shares, compared to its average volume of 1,092,121. The stock has a market capitalization of $4.17 billion, a P/E ratio of -106.42, a price-to-earnings-growth ratio of 0.68 and a beta of 0.75. The company has a quick ratio of 1.64, a current ratio of 1.83 and a debt-to-equity ratio of 0.31. Lantheus Holdings, Inc. has a 1-year low of $22.20 and a 1-year high of $73.78. The firm’s 50 day moving average is $63.64 and its 200-day moving average is $45.56.
Lantheus (NASDAQ:LNTH – Get Rating) last released its quarterly earnings data on Friday, April 29th. The medical equipment provider reported $0.97 EPS for the quarter, beating the consensus estimate of $0.46 by $0.51. The company had revenue of $208.90 million during the quarter, compared to the consensus estimate of $165.30 million. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The firm’s revenue for the quarter was up 125.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 2.79 earnings per share for the current year.
A number of analysts recently issued reports on the company. B. Riley assumed coverage on Lantheus in a research note on Monday, May 9th. They set a “buy” rating and a $91.00 target price for the company. StockNews.com assumed coverage on shares of Lantheus in a research note on Thursday, March 31st. They set a “hold” rating for the company. Truist Financial raised their price target on shares of Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. Finally, SVB Leerink reaffirmed an “outperform” rating and set a $100.00 price target on shares of Lantheus in a research note on Monday, June 6th.
About Lantheus (Get Rating)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.